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Summary
Recent research of neurodegenerative diseases has
called attention to abnormal protein aggregates
found in brain lesions.  Alzheimer’s disease (AD)
and frontotemporal dementia with parkinsonism
linked to chromosome 17 (FTDP-17) are part of a
collective group of neurodegenerative diseases
termed taupathies and are characterized by
abnormal filamentous tau inclusions.  A_ amyloid
plaques and neurofibrillary tangles containing
hyperphosphorylated tau are invariant features of
AD. The role of tau in AD pathogenesis is
controversial.  However, multiple tau mutations
discovered in FTDP-17 add significance to tau’s
role in neurodegeneration.  To study AD, our lab
has identified different sites that become
abnormally phosphorylated in adult tau and the
potential role for dysfunctional phosphatases.  To
model FTDP-17, we and other labs have created
transgenic mice that either overexpress wild type
tau or express mutant tau.  These mice develop
clear neurodegenerative phenotypes.  Analogous to
tau aggregates, cytoplasmic inclusions known as
Lewy bodies are characteristic of Parkinson’s
disease (PD).  _- synuclein has been linked to both
familial and sporadic PD.  Following this discovery,
our lab has demonstrated that aggregated _-
synuclein appears in Lewy bodies of human
patients.  Transgenic mice and Drosophila models
expressing _-synuclein are being used to identify
suppressors and enhancers of disease.
Investigating the role of tau and _-synuclein in
neurodegenerative diseases can aid in the
development of effective treatments.
Introduction
A common theme among many neurodegenerative
disorders is the accumulation of abnormal proteins in
the brain.  Taupathies and synucleinopathies are
collectively grouped diseases involving protein
aggregates of abnormal tau or _-synuclein,
respectively. Frontotemporal dementia with
parkinsonism linked to chromosome 17 (FTDP-17),
Alzheimer’s disease (AD), and Parkinson’s disease
(PD) belong to the above groups of diseases, though
they display diverse phenotypes.
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FTDP-17 and AD are adult-onset
neurodegenerative dementias characterized by memory
deficits and the progressive loss of cognitive abilities1.
The clinical symptoms of FTDP-17 also include
behavioral disturbances, muscle rigidity, body tremor,
bradykinesia, and amyotrophy (muscle weakness).  AD
symptoms relate more to deficits in problem solving,
language, judgment, and behavior1.  Whereas FTDP-17
causes atrophy in the frontal neocortex, AD primarily
affects neurons in the temporal lobe, hippocampus, and
the parietal association cortices1.  Neurofibrillary
tangles containing hyperphosphorylated tau, a
microtubule-associated protein, are distinct features of
both FTDP-17 and sporadic and familial AD1, 2 (Figure
1).
Along with AD, PD is also a common
neurodegenerative disorder in the aging population.
Symptoms of PD include resting tremor, rigidity,
bradykinesia, gait disturbance, and postural instability3.
Pathologically, PD is accompanied by a loss of
dopaminergic neurons in the substantia nigra and by
the presence of Lewy bodies (Figure 1).  Both sporadic
and familial PD involve misfolding of the _-synuclein
protein (Figure 1).  Sporadic PD, though less
understood, is more widespread than familial PD.
Oxidative stress and mitochondrial dysfunction are
thought to play important roles in sporadic PD3, 4.  The
familial form, however, allows the development of
transgenic models and offers insights into the role of α-
synuclein and the pathogenesis of PD3.
Twists and Tangles
The prominent features of AD are extracellular amyloid
plaques and intracellular neurofibrillary tangles
containing paired helical filaments (PHF)1, 5.  Amyloid
plaques are primarily composed of amyloid-_-peptides
(A_), which are produced by cleavage of an amyloid
precursor protein (APP)1.  Mutations in APP lead to
overproduction of insoluble A_ peptide and its
deposition in the neuritic plaques1, 2. Although
hyperphosphorylated tau was identified in neurofibrillary
tangles (Figure 1), amyloid plaques were believed to be
the dominant cause of neurodegeneration in AD.
However, since tau inclusions were also seen in FTDP-
17 patients, tau became a candidate gene for FTDP-17
pathology6.  The discovery of several tau gene
mutations added further significance to tau, indicating
that abnormal tau might be a primary cause of
neurodegeneration7.
The protein tau itself is found abundantly in
axons of nerve cells and to some extent in glial cells.  It
binds to microtubules, stabilizes them, and facilitates
transport of vesicles1.  Six isoforms of the tau protein
are present in the adult human brain1, 2.  All six isoforms
are produced by alternative splicing of the tau gene,
and they differ by amino acid length and the number of
tandem repeats (3R or 4R) of 31 or 32 amino acids1.
The microtubule binding domains are located on the
tandem repeats2.  Whereas the adult brain contains all
six isoforms of tau, the fetal brain only expresses the
shortest tau isoform2.   Moreover ,  the
hyperphosphorylation of tau is also developmentally
regulated.  Fetal tau is found to be more highly
phosphorylated in immature brain than in adult brain.
The level of phosphorylation for all six isoforms
decreases with age2.
Figure 1.  Role of tau and _-synuclein in neurodegenerative diseases
In FTDP-17, mutations in tau have been linked to the presence of neurofibrillary tangles containing hyperphosphorylated tau.  The
role of tau in pathogenesis of Alzheimer’s disease is uncertain, but hyperphosphorylated tau has been identified in neurofibrillary
tangles.  In Parkinson’s disease, mutations in _-synuclein have been identified, but how misfolded _-synuclein or Lewy bodies lead
to neurodegeneration is unclear.
Mutations of tau in FTDP-17 are either missense, silent,
and deletion mutations in the exons or intronic
mutations7, 8, 9.  Intronic mutations near exon 10 (E10) of
the tau gene increase the ratio of 4R-tau to 3R-tau,
which is ~1 in the normal adult brain 7, 8.    Studies
suggest that mutations in tau destabilize an RNA stem-
loop structure that follows E10, leading to an increased
encoding of E10 and an increased proportion of 4R-
tau7, 8.  In FTDP-17, hyperphosphorylated tau forms into
twisted filaments that are different from PHF tau of AD6.
 
Following Mutant Tau
Soon after tau gene mutations were reported, our lab
pursued investigation of the pathological mechanisms
that cause FTDP-17.  One of our studies demonstrates
that splicing of E10 involves three different regulatory
elements10.  Missense tau mutations can act on an
exon splicing enhancer within E10, and thereby
increase the inclusion or exclusion of E10 in tau
transcripts.  Silent tau mutations can also increase
inclusion of E10 by destroying the exon splicing silencer
element within E10.  Lastly, intronic mutations in
intronic sequences flanking the 5’ splice site of E10
enhance encoding of E1010.  Since the tau gene is
regulated by several elements, tau mutations can cause
FTDP-17 through multiple mechanisms.
Tau Tangles Shy Away from Microtubules
Our lab has also analyzed the interaction between
mutant tau and microtubules.  Bacterial cells expressing
recombinant tau protein with missense mutations show
reduced binding of tau to microtubules10.  Furthermore,
the ability of tau to promote microtubule assembly is
also reduced10.
A similar study has also been performed on
Chinese hamster ovary (CHO) cells. The resulting
pathological phenotypes included formation of insoluble
tau aggregates and decreased microtubule binding11.
Both of these studies find that decreased levels of
microtubule binding correlate with increased amounts of
insoluble, unbound tau in the cytoplasm, which could
eventually lead to hyperphosphorylation and
aggregation of tau10, 11.
Of Mice and Tau
In order to model FTDP-17, we and other labs have
created transgenic mouse models that either
overexpress wild type tau or express mutant tau.
Transgenic mice overexpressing the shortest tau
isoform or the longest tau isoform developed
accumulations of insoluble, hyperphosphorylated tau.
Furthermore, these mice showed reduced fast axonal
transport, axonal degeneration, diminished
microtubules, and motor weakness12, 13.  Since these
mice developed neuropathological symptoms by
overexpression of normal tau, these studies also
support the role of tau in AD pathogenesis.
Other labs have created transgenic mice
expressing the common FTDP-17 mutation P301L.
Similar to human pathology, these mice showed
formation of neurofibrillary tangles and neuronal
lesions14, 15.  Behavioral and motor deficits characteristic
of FTDP-17 were also prominent in these transgenic
mice14.
Tau Tangles in the AD Arena
Since PHFs in AD are composed of
hyperphosphorylated forms of tau16, our lab set out to
identify the different sites on normal adult tau that
become abnormally phosphorylated.  Most of these
sites are serine (Ser) or theronine (Thr) residues.  In
addition, some of these sites, i.e. Ser262 and Ser396,
are located near microtubule-binding domains17, 18, 19.
Our lab proceeded to study whether these
abnormally phosphorylated sites might be the result of
inactivated protein phosphatases20-22.  Since the
phosphorylaion levels of tau isoforms decrease with
age in normal adult brain, activation of protein
phosphatases is one mechanism that might contribute
to dephosphorylation.  Protein phosphatases 2A
(PP2A) and 2B (PP2B) were shown to dephosphorylate
tau in developing rat brains20.  We have also
demonstrated that in human postmitotic neuron-like
cells (NT2N), disrupting the microtubule network results
in site-specific dephosphorylation of tau by PP2A21.
When NT2N cells are treated with inhibitors of PP2A,
results indicate increased tau phosphorylation,
decreased microtubule binding, destruction of selective
microtubules, and axon degeneration22.
Following this series of studies, we next
proceeded to compare mRNA distribution of PP2A in
control and AD hippocampus.  The level of PP2A
mRNA was significantly reduced in AD hippocampus23.
Our data indicates that protein phosphatases may play
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an important role in regulating the phosphorylation state
of tau, and their activity is decreased in AD neurons.
Along with inactivation of phosphatases,
activation of kinases can also be responsible for
abnormal tau phosphorylation.  One lab has shown that
increased activity of cyclin-dependent kinase 5 (cdk5)
also increases levels of tau phosphorylation in several
cell lines24.  Brain proline-directed kinases (BPDK) are
microtubule-associated proteins that have also been
shown to phosphorylate tau.  Furthermore, BPDK
phosphorylates sites that are found abnormally
phosphorylated in PHF tau25.
Enhanced Tau Tangles
As previously described, transgenic mouse models
overexpressing the shortest tau isoforms developed
neurofibrillary tangles12.  Moreover, similar to AD
patients, these tangles contained neurofilament (NF)
subunits12.  Our lab extended these findings by
designing transgenic mice that lacked neurofilaments26.
Thus, transgenic mice overexpressing the shortest tau
isoform were crossbred with knock-out mice lacking
neurofilaments.  As a result, tau aggregation was
delayed, weight loss was reduced, viability was
increased, and behavioral phenotypes were improved
when compared to transgenic mice with
neurofilaments26.  Therefore, we found that
neurofilaments may play a malevolent role in AD
pathogenesis by facilitating aggregation of tau.
Plaques and Tangles: Together at Last?
Whether it is amyloid plaques or tau tangles that
primarily cause neurodegeneration is highly
controversial.  Recently, however, two groups of
scientists present evidence that links tau aggregation to
amyloid plaques.  In one case, transgenic mice
expressing mutant tau protein were crossbred with
transgenic mice expressing mutant _-amyloid precursor
protein.  Although these mice developed amyloid
plaques at the same age, the levels of neurofibrillary
tangles increased significantly27.
Similarly, to link amyloid plaques to tau
tangles, another group injected A_ fibrils into brains of
transgenic mice expressing mutant tau28.  Findings
revealed that there is a fivefold increase in the number
of neurofibrillary tangles, and they begin to appear
shortly after injection of A_ fibrils28.   Thus, there is a
connection between amyloid plaques and tau tangles,
but how overproduction of A_ causes tau dysfunction is
unclear.  Also, it needs to be assessed whether these
mice develop AD symptoms such as dementia.
Nevertheless, these models provide a means to
develop therapies that can target amyloid plaques and
tau tangles27, 28.
Like Tau, Like _-Synuclein
Like tau, α-synuclein is part of the abnormal protein
aggregates found in PD. The familial form of PD, with
an autosomal-dominant inheritance pattern, was first
linked to a missense mutation (Ala30_Thr) in α -
synuclein by Polymeropoulos et al29.  Next, our lab
discovered a link between _-synuclein and Lewy
bodies, which are characteristic of PD.  Substantia
nigra neurons from PD patients stained positive for
Lewy bodies containing _-synuclein30.
We then moved on to demonstrate that wild
type and mutant _-synucleins (Ala30_Pro and Ala53_Thr)
self-aggregate in vitro31.  The solubility of wild type and
mutant _-synucleins decreased, and they formed into
elongated filaments.  _-Synuclein polymerization was
concentration and time dependent, suggesting that
initial conformational changes in _-synuclein might
serve as seeds for advanced polymerization31. Also, the
A53T mutant _-synuclein was most prone to aggregate,
and it may be a more pathogenic species than wild type
or A30P _-synuclein31.  When immunogold labeling was
done, the N- and C- terminal regions of _-synuclein
were less accessible and weakly labeled, thus implying
that these regions are involved in polymer formation
and are buried within filaments31.
Synaptic Role of _-Synuclein
Although the functions of _-synuclein are not clearly
understood, our lab has attempted to characterize the
role of this protein.  Using neuronal cultures, we found
that expression of _-synuclein was localized primarily in
presynaptic vesicles32.  Furthermore, antisense
inhibition of _-synuclein resulted in decreased pools of
synaptic vesicles at the presynaptic terminal.  Also, we
observed a decrease in levels of synapsin I and
synatophysin, proteins found in synaptic terminals32.
Our results suggest that one function of _-synuclein
might include maintenance of synaptic vesicle pools.
Modeling PD in Mice and Flies
To prove that _-synuclein aggregates are pathogenic,
our lab created transgenic mice that expressed A53T
mutant and wild type _-synuclein.  Transgenic mice
expressing the A53T mutant developed
neuropathological symptoms similar to PD patients33.
These included accumulations of _-synuclein inclusions
and severe movement disorders.   Thus, formation of
filamentous _-synuclein inclusions correlates with
disease onset33.
Other labs have used Drosophila models to
recapitulate features of PD34.  Transgenic flies
overexpressing wild type and mutant _-synuclein
displayed degeneration of dopamine neurons, formation
of _-synuclein inclusions, and motor impairments34.
Our lab has also used Drosophila to study
factors that enhance or suppress PD pathology35.  In
these models, dopaminergic neuronal loss was
prevented by expression of the molecular chaperone
Hsp70.  Although toxicity of _-synuclein was
suppressed in transgenic flies, no change in aggregate
pathology was evident35.  Also, interference with
endogenous chaperone activity enhanced toxicity of _-
synuclein35.  In addition, molecular chaperones were
found to be present in Lewy bodies of PD patients35.
Our data strongly suggests that molecular
chaperones might help prevent degeneration of
dopaminergic neurons by suppressing _-synuclein.  On
the other hand, _-synuclein toxicity might be enhanced
due to the trapping of chaperones in Lewy bodies35.
Increasing the activity of molecular chaperones might
prove to be an effective treatment in PD patients35. It
has yet to be determined, however, whether expression
of Hsp70 reverses PD symptoms, such as motor
impairments, in these transgenic flies.
_-synuclein Caught in a Triangle
Along with mutations in the _-synuclein gene, familial
PD has been associated with mutations in two other
genes, both of which are gaining considerable
importance.  Mutations in the parkin gene cause
autosomal recessive PD, where the onset of PD is seen
at an earlier age36.  As ubiquitin is known to be present
in _-synuclein Lewy bodies, one model hypothesizes
that the parkin protein regulates the ubiquitin
degradation pathway of _-synuclein37.
Figure 2.  Proposed Models for Parkin and UCH-L1 Interaction with _-Synuclein
The parkin ubiquitin complex polyubiquinates _-synuclein and prepares it for degradation (1).  Other environmental or genetic
factors might inhibit proper degradation of _-synuclein, causing accumulation and fibrillization of _-synuclein in Lewy bodies
(3).  Mutations in parkin can cause accumulation of nonubiquinated _-synuclein (2).  Loss of control of UCH-L1 ligase activity
could cause extension of polyubiquityl chains on _-synuclein and inhibit its degradation (5).  These ubiquitin additions require
no ATP and are thus different from ubiquitin additions by ligase complexes (4) (difference in Ub is indicated by gray or white
color).  Polyubiquityl chains themselves can inhibit proteosomal degradation (6).  Thus, in both cases, accumulation of
ubiquinated _-synuclein can cause formation of Lewy bodies or PD (7).
Recently, parkin was identified as an E3 ubiquitin ligase
that associates with a ubiquitin enzyme and a distinct
form of _-synuclein37.  Whereas normal parkin
ubiquinated _-synuclein, mutant parkin failed to bind _-
synuclein and caused an accumulation of
nonubiquinated _-synuclein37.  Therefore, it is proposed
that loss of parkin function leads to pathological
accumulation of _-synuclein, neuronal loss, and an
absence of ubiquitin-tagged Lewy bodies, a common
feature of autosomal recessive PD patients.  Wild-type
parkin is thought to polyubiquinate _-synuclein and
prepare it for proteosome degradation; however,
interference by other genetic or environmental factors
might prevent degradation of these proteins and lead to
formation of Lewy bodies37 (Figure 2).
A gene that has been linked to autosomal
dominant PD is ubiquitin C-terminal hydolase-L1 (UCH-
L1)38.  UCH-L1 was recently shown to possess ligase
activity that inhibited proteosomal degradation of _-
synuclein39.  UCH-L1 is capable of extending the
polyubiquitin chain of _-synuclein by ATP-independent
addition of ubiquitin molecules.  This process differs
form ubiquitylation by other ligases, such as E3, that
require ATP to be present39. Furthermore, it is
hypothesized that polyubiquinated _-synuclein or
polyubiquitin chains themselves inhibit proteosome
degradation.  Inhibition consequently promotes
aggregation and fibril formation of _-synuclein
pathogenic for PD39 (Figure 2).
Untangling the Problem
Although research of neurodegenerative diseases has
made great advances over the past decade, the
mechanisms of neurodegeneration are far from being
untangled.  Studying the role of tau and _-synuclein in
pathogenesis of FTDP-17, AD, and PD will allow
development of effective therapies and treatments.
Although it is unclear how tau and _-synuclein
abnormalities lead to neurodegeneration, many studies
have provided evidence for probable pathways.
Investigating tau mutations in FTDP-17 has
established that hyperphosphorylated tau aggregates
are sufficient to cause neurodegeneration.  Events
leading to hyperphosphorylation of tau in AD can
include an imbalance of phosphatase or kinase activity.
Emerging evidence links tau tangles to amyloid
plaques; however, how amyloid plaques lead to
increased tau dysfunction has yet to be established.
In PD, filamentous _-synuclein in Lewy
bodies have been linked to the onset of
neurodegenerative phenotypes.  It is still unclear how
pathogenic _-synuclein aggregates cause dopaminergic
cell death.  Models have also been proposed for how
mutant _-synuclein, parkin and UCH-L1 genes cause
PD.
Transgenic models made by our lab and
others reproduce important features of FTDP-17, AD,
and PD, and offer insights into pathogenesis of these
diseases.  Development of additional animal models will
be beneficial in finding potential cures and treatments
for neurodegenerative disorders.
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